Cullinan Therapeutics, Inc.
CGEMNasdaqCIK 1789972HealthcareFiscal year ends Dec 31
Reports and events: 105 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2024-03-1407:22 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-031143 |
| 2024-03-1407:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-031140 |
| 2024-01-0816:15 ET | 8-K/A | 2.02 Results of operations | 0000950170-24-002936 |
| 2024-01-0809:12 ET | 8-K | 2.01 Completion of an acquisition or disposition | 0000950170-24-002745 |
| 2023-11-0807:22 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-060679 |
| 2023-11-0807:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-060673 |
| 2023-08-1007:44 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-040964 |
| 2023-08-1007:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-040950 |
| 2023-06-1416:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0000950170-23-027958 |
| 2023-05-2517:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-154347 |
| 2023-05-1116:14 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0000950170-23-021253 |
| 2023-05-1116:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-142014 |
| 2023-04-2107:01 ET | DEF 14A | Proxy statementPeriod 2023-06-08 | 0001193125-23-109206 |
| 2023-03-0907:18 ET | 10-K | Annual reportPeriod 2022-12-31 | 0000950170-23-006839 |
| 2023-03-0907:11 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-065289 |
| 2023-02-1419:11 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-036285 |
| 2023-01-1916:40 ET | 8-K | 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-23-011002 |
| 2022-11-1407:20 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0000950170-22-024683 |
| 2022-11-1407:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-283667 |
| 2022-11-0208:28 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-22-275466 |
| 2022-10-2507:14 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-267965 |
| 2022-08-1007:24 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0000950170-22-016258 |
| 2022-08-1007:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-216798 |
| 2022-06-2716:15 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-182838 |
| 2022-06-2416:20 ET | 8-K | 5.07 Shareholder vote results | 0001193125-22-181528 |
| 2022-05-1607:11 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0000950170-22-009937 |
| 2022-05-1606:52 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-150830 |
| 2022-05-1206:11 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-22-147984 |
| 2022-04-2907:00 ET | DEF 14A | Proxy statementPeriod 2022-06-22 | 0001193125-22-130030 |
| 2022-03-1707:31 ET | 10-K | Annual reportPeriod 2021-12-31 | 0000950170-22-004002 |
| 2022-03-1707:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-22-077804 |
| 2022-03-0308:26 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-22-063699 |
| 2021-12-2907:01 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-368422 |
| 2021-12-1606:43 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-21-358521 |
| 2021-11-0907:09 ET | 10-Q | Quarterly reportPeriod 2021-09-30 | 0001564590-21-055440 |
| 2021-11-0906:57 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-21-323714 |
| 2021-10-1807:45 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-21-300558 |
| 2021-08-1007:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-21-241140 |
| 2021-08-1007:01 ET | 10-Q | Quarterly reportPeriod 2021-06-30 | 0001564590-21-042872 |
| 2021-07-0109:25 ET | 8-K | 5.07 Shareholder vote results | 0001193125-21-205693 |
| 2021-06-0409:07 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-21-182269 |
| 2021-05-2116:04 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-21-169247 |
| 2021-05-1406:46 ET | 10-Q | Quarterly reportPeriod 2021-03-31 | 0001564590-21-027796 |
| 2021-05-1406:39 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-21-161192 |
| 2021-04-2916:40 ET | DEF 14A | Proxy statementPeriod 2021-06-25 | 0001193125-21-140630 |
| 2021-03-3007:15 ET | 10-K | Annual reportPeriod 2020-12-31 | 0001564590-21-016312 |
| 2021-03-3006:27 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-21-098986 |
| 2021-02-2607:04 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-21-058343 |
| 2021-02-2217:14 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-21-050927 |
| 2021-01-1916:33 ET | SC 13D | Ownership report, active investor | 0001193125-21-011512 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 10, 2026, 16:50 ET. Listed shows no prices and gives no investment advice.